Insider · CIK 0001487179
Julie McHugh
Files at IRWD (IRONWOOD PHARMACEUTICALS INC), LNTH (Lantheus Holdings, Inc.). First filing Jun 11, 2025, latest Jun 17, 2026.
In brief
Julie McHugh files SEC Form 4 as director at IRWD (IRONWOOD PHARMACEUTICALS INC), and also at LNTH (Lantheus Holdings, Inc.). Since Jun 11, 2025, Julie McHugh has reported 0 open-market buys worth $0 and 2 open-market sells worth $504k, the latest filed on Jun 17, 2026.
A track record needs three past buys with six months of prices behind them; Julie McHugh has 0, so none is measured yet.
The newest scored trade: sold $80k of IRWD on Jun 16, 2026, filed Jun 17, 2026, scored 4 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $80k.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
IRWD: IRONWOOD PHARMACEUTICALS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
LNTH: Lantheus Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 4Weak | IRONWOOD PHARMACEUTICALS INC | $80k 21,571 shares | -8% | +481% from low-32% from high | |
| 31Weak | Lantheus Holdings, Inc. | $424k 5,192 shares | -17% | +13% from low-29% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 16, 2026 | IRWD IRONWOOD PHARMACEUTICALS, INC. | 21,571 0.01% of outstanding | $80k | Jun 16, 2026 | none |
| Jun 9, 2025 | LNTH Lantheus Holdings, Inc. | 5,192 0.01% of outstanding | $424k | Jun 9, 2025 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | IRWD IRONWOOD PHARMACEUTICALS INC | AGrant or award Class A Common Stock10b5-1 | +63,481 | $0.00 | $0 | 272,320 | Jun 17, 2026 |
| Jun 16, 2026 | IRWD IRONWOOD PHARMACEUTICALS INC | SOpen-market sale Class A Common Stock10b5-1 | -21,571 | $3.73 | $80k | 250,749 | Jun 17, 2026 |
| May 14, 2026 | LNTH Lantheus Holdings, Inc. | AGrant or award Common Stock | +4,137 | $0.00 | $0 | 30,099 | May 18, 2026 |
| Jun 10, 2025 | IRWD IRONWOOD PHARMACEUTICALS INC | AGrant or award Class A Common Stock | +45,000 | $0.00 | $0 | 208,839 | Jun 12, 2025 |
| Jun 9, 2025 | LNTH Lantheus Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -5,192 | $81.62 | $424k | 25,962 | Jun 11, 2025 |
| May 14, 2025 | LNTH Lantheus Holdings, Inc. | AGrant or award Common Stock | +2,537 | $0.00 | $0 | 31,154 | May 16, 2025 |
| May 14, 2025 | LNTH Lantheus Holdings, Inc. | AGrant or award Stock Option (right to buy)derivative | +4,543 | $0.00 | $0 | 4,543 | May 16, 2025 |
Questions about Julie McHugh
Answered from the filings on this page, as of the latest one.
Is Julie McHugh buying or selling?
In the last 12 months Julie McHugh reported 0 open-market buys worth $0 and 1 open-market sell worth $80k on SEC Form 4; the latest was sold $80k of IRWD on Jun 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Julie McHugh's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Julie McHugh has 0.
Where does Julie McHugh file Form 4?
Julie McHugh has filed Form 4 at IRWD (IRONWOOD PHARMACEUTICALS INC); LNTH (Lantheus Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.